Curetis expands its diagnostic platform

Curetis N.V. and the European Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25 million senior, unsecured loan. The financing is the first growth capital loan under the European Growth Finance Facility (EGFF). It is backed by a guarantee from the European Fund for Strategic Investments (EFSI).

Dr. Oliver Schacht, CEO of Curetis.
Dr. Oliver Schacht, CEO of Curetis.

EFSI is an essential pillar of the Investment Plan for Europe (IPE), under which the EIB and the European Commission are working as strategic partners to support investments and bring back jobs and growth to Europe.

The debt facility features typical market interest rates with more than half of the interest payments deferred into the repayment at maturity. The funding can be drawn in up to five tranches within the next 24 months; each tranche is to be repaid upon maturity five years after draw-down. The flexible terms allow Curetis to fund up to 50% of its expected medium-term R&D project requirements (incl. R&D staff costs, external R&D operating expenses, corresponding capital expenditures for R&D etc.) and will enable Curetis to fund the strategic expansion and enhancement of its Unyvero Platform and products.

Specifically, the funds will allow the further development and validation of complementary technology assets and corresponding IP and the funding of clinical trials. In addition, the funds will support the integration of the recently acquired GEAR database and assets. “We are proud to get the support of the EIB,” said Dr. Oliver Schacht, CEO of Curetis. “The funding will allow us to further expand our leading position in molecular diagnostics by integrating complementary know-how and assets into our proprietary Unyvero Platform. Moreover, we will be able to significantly accelerate our R&D activities and develop a broader pipeline of applications for our Unyvero platform.

EIB Vice President Ambroise Fayolle, responsible for Germany and innovation in the EU Bank, emphasized: “This transaction demonstrates EIB´s firm commitment to support early-stage and fast-growing companies in Europe. Supporting R&D is one of the EIB’s key goals, and small midcaps like Curetis are instrumental for Europe’s knowledge economy, as they pursue innovation-intensive businesses and employ highly qualified people. Most importantly, this investment will contribute to accelerating the development and market launch of new diagnostics tests, helping to improve the diagnosis and survival rates of critically ill patients in Europe as well as to counteract increasing antibiotic resistance.”

European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said: "The EFSI is playing a crucial role in ensuring that innovative smaller businesses have access to the finance they need to fund their research activities. Curetis is undertaking cutting-edge research on advanced diagnostics. The EFSI can help firms like Curetis reach the next level, while ensuring that Europe maintains its status as a centre of innovate healthcare product development."

Source: Curetis N.V.


Read all latest stories

Related articles


Infection control

From alcohol to cancer detection

Clinical trials are under way at two NHS hospitals in England to assess breathalyser technology to detect lung cancer. Phase I clinical trials of a diagnostic breathalyser developed by…


Rapid detection

Molecular diagnostic test for Covid-19, Flu, RSV receives CE mark

A new rapid molecular diagnostic test from Cepheid has received the CE mark for distribution in the European market. The test, called Xpert Xpress CoV-2/Flu/RSV plus, is designed for qualitative…


Surprising similarities

These are the top 25 medical lab tests around the world

A recent study can help governments understand which diagnostic laboratory tests are most important when developing universal health coverage systems. Researchers from five countries found that…

Related products

Lifotronic - FA-160 Immunofluorescence Analyzer


Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
Subscribe to Newsletter